1. Home
  2. CSTL vs BLMN Comparison

CSTL vs BLMN Comparison

Compare CSTL & BLMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

HOLD

Current Price

$38.83

Market Cap

661.7M

Sector

Health Care

ML Signal

HOLD

BLMN

Bloomin' Brands Inc.

HOLD

Current Price

$6.76

Market Cap

586.3M

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSTL
BLMN
Founded
2007
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Restaurants
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
661.7M
586.3M
IPO Year
2019
2012

Fundamental Metrics

Financial Performance
Metric
CSTL
BLMN
Price
$38.83
$6.76
Analyst Decision
Strong Buy
Sell
Analyst Count
6
7
Target Price
$38.67
$8.29
AVG Volume (30 Days)
439.7K
2.3M
Earning Date
11-03-2025
11-06-2025
Dividend Yield
N/A
10.22%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$343,530,000.00
$3,952,793,000.00
Revenue This Year
$1.69
$2.19
Revenue Next Year
N/A
$0.32
P/E Ratio
N/A
$18.12
Revenue Growth
10.15
7.72
52 Week Low
$14.59
$5.90
52 Week High
$40.61
$13.25

Technical Indicators

Market Signals
Indicator
CSTL
BLMN
Relative Strength Index (RSI) 71.92 48.57
Support Level $38.69 $6.58
Resistance Level $40.54 $6.93
Average True Range (ATR) 1.58 0.33
MACD -0.18 0.05
Stochastic Oscillator 75.59 62.88

Price Performance

Historical Comparison
CSTL
BLMN

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

About BLMN Bloomin' Brands Inc.

Bloomin Brands Inc operates as a casual dining restaurant company. The company's brand includes Outback Steakhouse, Carrabba's Italian Grill, Bonefish Grill, and Fleming's Prime Steakhouse and Wine Bar. The company owns and operates its restaurants, and the remainder is franchised. It derives revenue mainly from the United States, but the company has a presence in Brazil and South Korea with company-owned Outbacks and Carrabbas. In addition, it also has exposure to several countries, predominantly in Asia, principally through franchising. The Company aggregates its operating segments into two reportable segments, U.S. and international. The U.S. segment includes all restaurants operating in the U.S. while restaurants operating outside the U.S. are included in the international segment.

Share on Social Networks: